 If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL PLANEGGMUNICH, GERMANY and WILMINGTON, DE ACCESSWIRE June 25, 2021 MorphoSys AG FSE:MORNASDAQ:MOR and Incyte NASDAQ:INCY today announced that the European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has issued a positive opinion recommending the conditional marketing authorization of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL who are not eligible for autologous stem cell transplantation ASCT. The CHMPs positive opinion of tafasitamab is a pivotal step towards addressing an urgent unmet medical need for the 30-40 of patients with relapsed or refractory DLBCL who do not respond to initial therapy or relapse thereafter, said Steven Stein, M.D. 